0001209191-21-030397.txt : 20210505 0001209191-21-030397.hdr.sgml : 20210505 20210505171309 ACCESSION NUMBER: 0001209191-21-030397 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210503 FILED AS OF DATE: 20210505 DATE AS OF CHANGE: 20210505 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McAnear Justin J. CENTRAL INDEX KEY: 0001786386 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39035 FILM NUMBER: 21894521 MAIL ADDRESS: STREET 1: 10X GENOMICS, INC. STREET 2: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: 10x Genomics, Inc. CENTRAL INDEX KEY: 0001770787 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 455614458 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 BUSINESS PHONE: (925) 401-7300 MAIL ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 FORMER COMPANY: FORMER CONFORMED NAME: 10X Genomics, Inc. DATE OF NAME CHANGE: 20190315 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-05-03 0 0001770787 10x Genomics, Inc. TXG 0001786386 McAnear Justin J. C/O 10X GENOMICS, INC. 6230 STONERIDGE MALL ROAD PLEASANTON CA 94588 0 1 0 0 Chief Financial Officer Class A Common Stock 2021-05-03 4 M 0 10000 5.04 A 40357 D Class A Common Stock 2021-05-03 4 S 0 600 189.5718 D 39757 D Class A Common Stock 2021-05-03 4 S 0 1900 190.6269 D 37857 D Class A Common Stock 2021-05-03 4 S 0 2700 191.7716 D 35157 D Class A Common Stock 2021-05-03 4 S 0 3706 192.4558 D 31451 D Class A Common Stock 2021-05-03 4 S 0 794 193.4001 D 30657 D Class A Common Stock 2021-05-03 4 S 0 200 194.92 D 30457 D Class A Common Stock 2021-05-03 4 S 0 100 198.09 D 30357 D Stock Option (right to buy) 5.04 2021-05-03 4 M 0 10000 0.00 D 2028-11-02 Class A Common Stock 10000 430159 D This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $189.12 to $189.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $190.10 to $191.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $191.08 to $192.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $192.06 to $192.995. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $193.07 to $193.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This option, originally for 600,000 shares, of which 169,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. /s/ Eric S. Whitaker, as Attorney-in-Fact 2021-05-05